Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has earned a consensus rating of “Buy” from the twenty-five analysts that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $141.95.
A number of equities research analysts recently commented on the stock. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, April 9th. Oppenheimer restated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, March 19th. Wedbush set a $251.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 5th. UBS Group raised their price objective on shares of Intercept Pharmaceuticals to $139.00 and gave the company a “buy” rating in a research report on Thursday, March 28th. Finally, Royal Bank of Canada upgraded shares of Intercept Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research report on Friday, March 1st.
In related news, Director Luca Benatti acquired 1,200 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was purchased at an average cost of $83.50 per share, for a total transaction of $100,200.00. Following the transaction, the director now directly owns 7,556 shares of the company’s stock, valued at approximately $630,926. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $95.00, for a total value of $190,000.00. Following the transaction, the insider now owns 41,499 shares of the company’s stock, valued at $3,942,405. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,562 shares of company stock valued at $427,196. Insiders own 5.00% of the company’s stock.
Several institutional investors have recently modified their holdings of ICPT. Advisors Asset Management Inc. grew its stake in Intercept Pharmaceuticals by 112.7% in the fourth quarter. Advisors Asset Management Inc. now owns 14,243 shares of the biopharmaceutical company’s stock worth $1,436,000 after purchasing an additional 7,547 shares during the period. Rhumbline Advisers grew its stake in Intercept Pharmaceuticals by 48.1% in the fourth quarter. Rhumbline Advisers now owns 29,139 shares of the biopharmaceutical company’s stock worth $2,937,000 after purchasing an additional 9,470 shares during the period. Canada Pension Plan Investment Board purchased a new stake in Intercept Pharmaceuticals in the fourth quarter worth $2,260,000. LPL Financial LLC grew its stake in shares of Intercept Pharmaceuticals by 0.3% in the fourth quarter. LPL Financial LLC now owns 74,815 shares of the biopharmaceutical company’s stock worth $7,541,000 after acquiring an additional 254 shares during the last quarter. Finally, California Public Employees Retirement System grew its stake in shares of Intercept Pharmaceuticals by 19.0% in the fourth quarter. California Public Employees Retirement System now owns 29,865 shares of the biopharmaceutical company’s stock worth $3,010,000 after acquiring an additional 4,765 shares during the last quarter. Hedge funds and other institutional investors own 76.20% of the company’s stock.
NASDAQ:ICPT traded up $0.16 during mid-day trading on Monday, reaching $79.57. The stock had a trading volume of 833,858 shares, compared to its average volume of 599,731. The company has a quick ratio of 3.72, a current ratio of 3.72 and a debt-to-equity ratio of 19.41. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -7.33 and a beta of 1.44. Intercept Pharmaceuticals has a twelve month low of $73.01 and a twelve month high of $133.74. The firm’s 50 day moving average price is $83.47.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.57) by ($0.46). The firm had revenue of $52.25 million during the quarter, compared to analyst estimates of $52.15 million. Intercept Pharmaceuticals had a negative net margin of 162.49% and a negative return on equity of 617.23%. Intercept Pharmaceuticals’s revenue for the quarter was up 45.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($3.22) EPS. On average, equities research analysts forecast that Intercept Pharmaceuticals will post -10.1 earnings per share for the current year.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.